HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Jeffrey H Meyer Selected Research

Monoamine Oxidase (MAO)

1/2016Elevated Monoamine Oxidase-A Distribution Volume in Borderline Personality Disorder Is Associated With Severity Across Mood Symptoms, Suicidality, and Cognition.
10/2015Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive and Violent Male Offenders with Antisocial Personality Disorder and High Psychopathic Traits: An [(11)C] Harmine Positron Emission Tomography Study.
1/2015Relationship of monoamine oxidase-A distribution volume to postpartum depression and postpartum crying.
8/2014Greater monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled harmine positron emission tomography.
3/2014Elevated monoamine oxidase a binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms.
11/2012Convergent effects of acute stress and glucocorticoid exposure upon MAO-A in humans.
7/2012Mechanistic role for a novel glucocorticoid-KLF11 (TIEG2) protein pathway in stress-induced monoamine oxidase A expression.
3/2012Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study.
9/2011The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder.
5/2010Elevated brain monoamine oxidase A binding in the early postpartum period.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Jeffrey H Meyer Research Topics

Disease

14Major Depressive Disorder (Major Depressive Disorders)
03/2015 - 01/2003
5Postpartum Depression (Post-Natal Depression)
06/2015 - 05/2010
2Mood Disorders (Mood Disorder)
01/2016 - 08/2014
2Neurodegenerative Diseases (Neurodegenerative Disease)
08/2014 - 03/2012
2Parkinson Disease (Parkinson's Disease)
11/2008 - 09/2008
1Borderline Personality Disorder (Personality Disorders, Borderline)
01/2016
1Antisocial Personality Disorder (Antisocial Personality)
10/2015
1Dementia (Dementias)
08/2014
1Weight Gain
03/2014
1Hyperphagia
03/2014
1Disorders of Excessive Somnolence (Hypersomnia)
03/2014
1Depressive Disorder (Melancholia)
07/2012
1Alzheimer Disease (Alzheimer's Disease)
11/2008
1Schizophrenia (Dementia Praecox)
03/2007

Drug/Important Bio-Agent (IBA)

11Monoamine Oxidase (MAO)IBA
01/2016 - 12/2009
4Tuberculin (PPD)IBA
06/2015 - 06/2014
3Harmine (Telepathine)IBA
10/2015 - 03/2012
3Serotonin (5 Hydroxytryptamine)IBA
12/2009 - 01/2003
3Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA
09/2008 - 03/2007
23- amino- 4- (2- dimethylaminomethylphenylsulfanyl)benzonitrileIBA
09/2008 - 09/2007
14-aminospiroperidolIBA
10/2015
1FluorineIBA
03/2015
1GlucocorticoidsIBA
07/2012
1Neurotransmitter Agents (Neurotransmitter)IBA
07/2012
1beta Adrenergic ReceptorsIBA
11/2008
1LigandsIBA
07/2008
1Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA
05/2008
1Serotonin Uptake Inhibitors (Serotonin Reuptake Inhibitors)IBA
09/2007
1Dopamine (Intropin)FDA LinkGeneric
03/2007
1salicylhydroxamic acid (SHAM)IBA
10/2004

Therapy/Procedure

1Therapeutics
03/2012